Published by Josh White on 10th January 2020
(Sharecast News) - Intellectual property commercialisation company Frontier IP announced on Friday that its portfolio company Exscientia, which focuses on artificial intelligence (AI) driven drug discovery, has entered into a collaboration with Bayer focused on cardiovascular disease and oncology.